FDA Finds 3 Deficiencies at Nara Organics as Botulism Probe Widens
Updated
Updated · The Guardian · Jul 3
FDA Finds 3 Deficiencies at Nara Organics as Botulism Probe Widens
3 articles · Updated · The Guardian · Jul 3
Summary
An FDA report posted June 26 said inspectors found deficiencies at Nara Organics’ facilities after the company recalled infant formula and faced a late-June lawsuit alleging a baby contracted botulism.
Three California infant botulism cases from late April and May were linked in a June state advisory to Nara formula, though the FDA said there is still insufficient evidence that shared whole milk powder caused the contamination.
Nara said the May 2026 inspection was routine, involved three observations and did not prompt the FDA to recommend halting production; the agency said corrective actions are under review while it traces the root cause through supply-chain checks and sampling.
The case has also drawn in Organic West, which supplied milk powder used by both Nara and ByHeart, whose November recall was tied to an outbreak that led to 48 hospitalizations across 17 states.
The episode lands as critics say Trump-era FDA cuts weakened formula oversight: former commissioner Martin Makary told Congress the agency lost about 3,100 employees, and state regulators reported nearly 2,000 recall checks in the first week of the ByHeart response versus 21 by the FDA.
Beyond bacterial recalls, what hidden chemical dangers are lurking in infant formula across the United States?
How can parents trust 'premium' formula if its suppliers can evade direct FDA safety inspections?
2026 Nara Organics Infant Formula Botulism Outbreak: Root Causes, Regulatory Gaps, and Urgent Calls for Reform
Overview
In June 2026, an outbreak of infant botulism was linked to Nara Organics Powdered Infant Formula, which had been distributed nationally in the United States for nearly a year. The extended incubation period of the illness made it difficult to quickly identify and attribute cases, even as public awareness of the recall increased. Health authorities responded by urging parents to stop using the formula and to monitor their infants for symptoms for at least a month. This incident exposed major weaknesses in supply chain traceability and regulatory oversight, highlighting the urgent need for stronger safety measures and clearer communication to protect public health.